Physician profile
Marek A Buczek
NPI 1093748113
$2,848.32
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $29.21 · 2021: $843 · 2022: $668 · 2023: $32.55 · 2024: $16.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.99 | 2021-2024 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $402.43 | 2019-2021 | |
| Lilly USA, LLC | $312.03 | 2019-2022 | |
| Biogen, INC. | $147.73 | 2019-2021 | |
| Genzyme Corporation | $101.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $100.47 | 2019-2022 | |
| Genentech USA, INC. | $85.48 | 2019-2021 | |
| Csl Behring | $80.96 | 2019 | |
| Amgen INC. | $77.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $75.93 | 2021 | |
| Emd Serono, INC. | $70.47 | 2019 | |
| Lundbeck LLC | $68.86 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $53.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.76 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.98 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $45.64 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $36.53 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $36.02 | 2019 | |
| Ucb, INC. | $34.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.79 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.44 | 2019 | |
| Assertio Therapeutics, INC. | $19.83 | 2019 | |
| Eisai INC. | $19.70 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.90 | 2021 | |
| Acorda Therapeutics, INC | $16.57 | 2019 | |
| Si-Bone, INC. | $16.26 | 2022 | |
| Aquestive Therapeutics, INC. | $16.04 | 2019 | |
| Promius Pharma LLC | $13.87 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.79 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marek Buczek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.